Adoptive Virus-Specific T Cell Therapy for Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation: Current Strategies and Future Perspectives
4 affiliations
- 1Department of Haematology, Haemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany
- 2German Center for Infection Research (DZIF, TTU-IICH), Hannover-Braunschweig Site, 30625 Hannover, Germany
- 3Miltenyi, 51429 Bergisch-Gladbach, Germany
- 4Institute of Virology, Hannover Medical School, 30625 Hannover, Germany
Abstract
Viral infections remain a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT), particularly in patients with delayed immune reconstitution or prolonged immunosuppression. Although antiviral drugs have substantially reduced the incidence of viral disease, their use is limited by toxicity, resistance, and the inability to restore long-term antiviral immunity. Adoptive transfer of virus-specific T cells represents a targeted immunotherapeutic strategy to re-establish pathogen-specific immune responses while minimizing the risk of graft-versus-host disease (GvHD). This review focuses on the development and clinical application of adoptive virus-specific T cell therapy after allogeneic HSCT, with particular emphasis on cytomegalovirus (CMV). We summarize the evolution of adoptive antiviral T cell therapy, compare current manufacturing and selection strategies, and critically review available clinical evidence regarding efficacy, persistence, safety, and alloreactivity. In addition to CMV-directed products, we discuss approaches targeting Epstein–Barr virus (EBV), adenovirus (AdV), and other clinically relevant pathogens in the context of multipathogen-specific T cell products and third-party donor approaches. We further address current knowledge on immune monitoring, factors influencing antiviral immune reconstitution, as well as practical challenges that still limit broader clinical use. Finally, we discuss emerging strategies to improve product standardization, availability, and integration of adoptive T cell therapy with modern antiviral prophylaxis and graft-engineering approaches.
Related
- Viral Respiratory Infections Diagnosed by Multiplex PCR after Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Incidence and Outcome
- The role of allogeneic hematopoietic stem cell transplantation in adults with mature T‐cell lymphomas
- Case Report: SAPHO syndrome mimicking osseous relapse after haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia
- Secondary Pulmonary Alveolar Proteinosis after Allogeneic Hematopoietic Stem Cell Transplantation in the Setting of an Respiratory Syncytial Virus Infection: A Case Report
- TP53-mutated Therapy-related Leukemia with the Der(5;17)(p10;q10) Chromosomal Abnormality Following Chemotherapy for Acute Promyelocytic Leukemia Bridged to Allogeneic Hematopoietic Stem Cell Transplantation Using CPX-351
BibTeX
@article{weissinger2026adoptive,
title = {{Adoptive Virus-Specific T Cell Therapy for Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation: Current Strategies and Future Perspectives}},
author = {Eva M. Weissinger and Lisa M. Schulz and Debora Basilio-Queiros and Michael Stadler and Penelope Kay-Fedorov},
journal = {Biomolecules},
year = {2026},
month = oct,
doi = {10.3390/biom16101465},
url = {https://www.mdpi.com/2218-273X/16/10/1465},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Adoptive Virus-Specific T Cell Therapy for Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation: Current Strategies and Future Perspectives
AU - Eva M. Weissinger
AU - Lisa M. Schulz
AU - Debora Basilio-Queiros
AU - Michael Stadler
AU - Penelope Kay-Fedorov
PY - 2026
DA - 2026/10/01
JO - Biomolecules
DO - 10.3390/biom16101465
UR - https://www.mdpi.com/2218-273X/16/10/1465
AB - Viral infections remain a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT), particularly in patients with delayed immune reconstitution or prolonged immunosuppression. Although antiviral drugs have substantially reduced the incidence of viral disease, their use is limited by toxicity, resistance, and the inability to restore long-term antiviral immunity. Adoptive transfer of virus-specific T cells represents a targeted immunotherapeutic strategy to re-establish pathogen-specific immune responses while minimizing the risk of graft-versus-host disease (GvHD). This review focuses on the development and clinical application of adoptive virus-specific T cell therapy after allogeneic HSCT, with particular emphasis on cytomegalovirus (CMV). We summarize the evolution of adoptive antiviral T cell therapy, compare current manufacturing and selection strategies, and critically review available clinical evidence regarding efficacy, persistence, safety, and alloreactivity. In addition to CMV-directed products, we discuss approaches targeting Epstein–Barr virus (EBV), adenovirus (AdV), and other clinically relevant pathogens in the context of multipathogen-specific T cell products and third-party donor approaches. We further address current knowledge on immune monitoring, factors influencing antiviral immune reconstitution, as well as practical challenges that still limit broader clinical use. Finally, we discuss emerging strategies to improve product standardization, availability, and integration of adoptive T cell therapy with modern antiviral prophylaxis and graft-engineering approaches.
SN - 2218-273X
ER -